Filing Flows › Comparisons › REGN vs VTRS
Regeneron Pharmaceuticals vs Viatris: REGN and VTRS compared
Regeneron Pharmaceuticals is the larger company: $5.1B of revenue in its latest quarter (Q3 2026) against $3.7B for Viatris (Q3 2026). Regeneron Pharmaceuticals is growing faster (+36% against -0.3% a year earlier). Regeneron Pharmaceuticals is more profitable, with an operating margin of 40.0% against 7.0%.
Where the money goes: REGN and VTRS
Regeneron Pharmaceuticals (REGN) · Q3 2026
Regeneron Pharmaceuticals, Q3 2026: revenue $5.1B (+36% year over year), operating margin 40.0%, net earnings $1.9B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
Viatris (VTRS) · Q3 2026
Viatris, Q3 2026: revenue $3.7B (-0.3% year over year), operating margin 7.0%, net loss $325M, operating cash flow $899M. The chart follows the revenue to costs, profit and cash.
| Regeneron Pharmaceuticals (REGN) | Viatris (VTRS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $5.1B | $3.7B |
| Revenue growth, Y/Y | +36% | -0.3% |
| Operating margin | 40.0% | 7.0% |
| Net earnings | $1.9B | −$325M |
| Net margin | 38.1% | -8.7% |
| Operating cash flow | $1.8B | $899M |
| Free cash flow | $1.5B | $814M |
| Market value | $95.3B | $22.1B |
| P/E | 20.0× | — |
| Analysts’ mean target | $977.93 | $21.00 |
Where the revenue comes from
Regeneron Pharmaceuticals
- Collaboration revenue: $3.0B (59%)
- Net product sales: $1.8B (35%)
- Other revenue: $310M (6%)
- Lynozyfic: $19.0M (0%)
Viatris
- Brands: $2.5B (66%)
- Lipitor: $452M (12%)
- EpiPen® Auto-Injectors: $156M (4%)
- Lyrica ®: $114M (3%)
Questions
Which is bigger, Regeneron Pharmaceuticals or Viatris?
Regeneron Pharmaceuticals is the larger company: $5.1B of revenue in its latest quarter (Q3 2026) against $3.7B for Viatris (Q3 2026).
Is Regeneron Pharmaceuticals or Viatris growing faster?
Regeneron Pharmaceuticals is growing faster (+36% against -0.3% a year earlier).
Which is more profitable, Regeneron Pharmaceuticals or Viatris?
Regeneron Pharmaceuticals is more profitable, with an operating margin of 40.0% against 7.0%.
More: Regeneron Pharmaceuticals earnings · how Regeneron Pharmaceuticals makes money · Viatris earnings · how Viatris makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 30, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.